MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jdin.2022.09.006

Медицинская библиотека · JAAD international · 2022

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

Bosma Angela L, Ouwerkerk Wouter, Heidema Madeline J, Prieto-Merino David, Ardern-Jones Michael R, Beattie Paula, Brown Sara J, Ingram John R, Irvine Alan D, Ogg Graham, Patel Prakash, Reynolds Nick J, Hearn R M Ross, Wan Mandy, Warren Richard B, Woolf Richard T, Hyseni Ariënna M, Gerbens Louise A A, Spuls Phyllis I, Flohr Carsten, Middelkamp-Hup Maritza A, TREAT NL registry and UK-Irish A-STAR Study Groups

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.

OBJECTIVE

To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type.

METHODS

In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated.

RESULTS

A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P < .001), more often had follicular eczema (22.1% vs 2.6%; P < .001), higher baseline Eczema Area and Severity Index (EASI) scores (20.1 vs 14.9; P = .009), less allergic contact dermatitis (30.9% vs 47.4%; P = .03), and less previous phototherapy use (39.7% vs 59.0%; P = .008). When comparing DST and LST corrected for covariates including baseline EASI, DST showed greater mean EASI reduction between baseline and 6 months with only dupilumab (16.7 vs 9.7; adjusted P = .032). No differences were found for adverse events for any treatments (P > .05).

LIMITATIONS: Unblinded, non-randomized.

CONCLUSION

Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

Для цитирования: Bosma Angela L, Ouwerkerk Wouter, Heidema Madeline J, Prieto-Merino David, Ardern-Jones Michael R, Beattie Paula, Brown Sara J, Ingram John R, Irvine Alan D, Ogg Graham, Patel Prakash, Reynolds Nick J, Hearn R M Ross, Wan Mandy, Warren Richard B, Woolf Richard T, Hyseni Ariënna M, Gerbens Louise A A, Spuls Phyllis I, Flohr Carsten, Middelkamp-Hup Maritza A, TREAT NL registry and UK-Irish A-STAR Study Groups. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.. JAAD international. 2022. DOI: 10.1016/j.jdin.2022.09.006.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.